| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | SELL | BUY |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 3.71▼ | 3.71▼ | 3.71▼ | 3.71▼ | 4.22▼ |
| MA10 | 3.62▲ | 3.62▲ | 3.69▼ | 3.92▼ | 3.36▲ |
| MA20 | 3.87▼ | 3.93▼ | 4.00▼ | 4.23▼ | 3.02▲ |
| MA50 | 4.41▼ | 4.54▼ | 4.19▼ | 3.21▲ | 2.92▲ |
| MA100 | 4.24▼ | 3.64▼ | 3.40▲ | 2.93▲ | 3.42▲ |
| MA200 | 3.44▲ | 3.09▲ | 2.95▲ | 2.89▲ | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.011▲ | -0.010▼ | -0.043▼ | -0.136▼ | 0.169▲ |
| RSI | 40.399▼ | 41.638▼ | 42.921▼ | 48.118▼ | 57.082▲ |
| STOCH | 48.570 | 48.570 | 43.400 | 28.244 | 55.123 |
| WILL %R | -58.378 | -58.378 | -63.850 | -68.750 | -61.428 |
| CCI | -29.713 | -31.884 | -47.351 | -99.777 | 37.140 |
|
Thursday, April 25, 2024 12:29 PM
Nutriband (NASDAQ: NTRB, NTRBW) , a pharmaceutical company with a special focus on transdermal technologies, today announced that it has selected
|
|
Thursday, April 25, 2024 04:29 AM
LOS ANGELES, April 25, 2024 (GLOBE NEWSWIRE) -- via IBN – Nutriband Inc. (NASDAQ: NTRB), a pharmaceutical company with a specific focus on ...
|
|
Wednesday, April 24, 2024 04:17 AM
Private Placement of $8.4 million has closed and will fund the commercial development of lead product AVERSA Fentanyl to NDA filingNutriband working to complete the commercial scale-up prior to perfor ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 25/04/24 | 3.76 | 3.87 | 3.64 | 3.65 | 14,167 |
| 24/04/24 | 3.68 | 3.89 | 3.63 | 3.85 | 3,583 |
| 23/04/24 | 3.70 | 3.7599 | 3.20 | 3.56 | 25,718 |
| 22/04/24 | 3.90 | 3.9314 | 3.4014 | 3.54 | 21,892 |
| 19/04/24 | 4.19 | 4.39 | 3.90 | 3.93 | 26,045 |
| 18/04/24 | 4.18 | 4.2501 | 4.00 | 4.04 | 24,010 |
| 17/04/24 | 4.10 | 4.44 | 4.10 | 4.27 | 8,928 |
| 16/04/24 | 3.98 | 4.3799 | 3.85 | 4.01 | 20,891 |
| 15/04/24 | 4.28 | 4.57 | 3.77 | 3.91 | 49,012 |
| 12/04/24 | 4.31 | 4.4399 | 4.2007 | 4.4099 | 27,018 |
|
|
||||
|
|
||||
|
|